Supervivencia de Bifidobacterium animalis DN-173 010 a través del tubo digestivo
Rochet V, L Rigottier-Gois, A Ledaire, C Andrieux, M Sutren, S Rabot, A Mogenet, J-L Bresson, S Cools, C Picard, N Goupil-Feuillerat and J Doré. Survivalof Bifidobacterium animalis DN-173 010 in the faecal microbiota after administration in lyophilised form or in fermented product - a randomised study in healthy adults. (Accepted in Journal of Molecular Microbiology & Biotechnology. 2007)
Collado M.C., Y. Moreno, J.M. Cobo, J.A. Mateos, M. Hernandez. Molecular detection of Bifidobacterium animalis DN-173 010 in human feces during fermented milk administration. Food Research International. 2006; 39: 530-535
Duez H, Pelletier C, Cools S, Aissi E, Cayuela C, Gavini F, Bouquelet S, Neut C and Mengaud J: A colony-immunoblotting method for quatitative detection of a Bifidobacterium animalis probiotic strain in human faeces. Journal of Applied Microbiology 2000. 88:1019-27
Pochart P, Marteau P, Bouhnik Y, Goderet I, Bourlioux P, Rambaud JC²²: Survival of Bifidobacteria ingested via fermented milk during their passage through the human small intestine: an in vivo study using intestinal perfusion. Am. J. Clin. Nutr. 1992;55:78-80
Pochart P, Marteau P, Bouhnik Y, Goderet I, Bourlioux P, Rambaud JC²²: Survival of Bifidobacteria ingested via fermented milk during their passage through the human small intestine: an in vivo study using intestinal perfusion. Am. J. Clin. Nutr. 1992;55:78-80
Pochart P, Marteau P, Bisetti N, Goderet I, Bourlioux P, Rambaud JC. Isolement des bifidobactéries dans les selles après ingestion prolongée de lait au bifidus (LB). Méd Mal Infect. 1990; 20: 75-78 (publication in French)
Tránsito intestinal
Méance S, Cayuela C, Raimondi A, Turchet P, Lucas C and Antoine JM. Recent advances in the use of functional foods: effects of the commercial fermented milk with Bifidobacterium animalis strain DN-173 010 and yoghurt strains on gut transit time in the elderly. Microbiological Ecology in Health and Disease 2003 ; 15 :15-22
Marteau P, Cuillerier E, Méance S, Gerhardt MF, Myara A, Bouvier M, Bouley C, Tondu F, Bommelaer G, Grimaud JC. Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women : a double blind, randomized, controlled study. Aliment Pharmacol. Ther. 2002 ; 16 : 587-593
Méance S, Cayuela C, Turchet P, Raimondi A, Lucas C and Antoine JM. A fermented milk with a Bifidobacterium probiotic strain DN-173 010 shortened oro-fecal gut transit time in elderly. Microbiological Ecology in Health and Disease. 2001; 13: 217-222
Bouvier M, Méance S, Bouley C, Berta JL and Grimaud JC. Effect of consumption of a milk fermented by the probiotic strain Bifidobacterium animalis DN-173 010 on colonic transit time in healthy humans Bioscience Microflora. 2001 ; 20 (2): 43-48.
Comfort digestivo
Méance S, Cayuela C, Raimondi A, Turchet P, Lucas C and Antoine JM. Recent advances in the use of functional foods: effects of the commercial fermented milk with Bifidobacterium animalis strain DN-173 010 and yoghurt strains on gut transit time in the elderly. Microbiological Ecology in Health and Disease 2003 ; 15 :15-22
Marteau P, Cuillerier E, Méance S, Gerhardt MF, Myara A, Bouvier M, Bouley C, Tondu F, Bommelaer G, Grimaud JC. Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women : a double blind, randomized, controlled study. Aliment Pharmacol. Ther. 2002 ; 16 : 587-593
Méance S, Cayuela C, Turchet P, Raimondi A, Lucas C and Antoine JM. A fermented milk with a Bifidobacterium probiotic strain DN-173 010 shortened oro-fecal gut transit time in elderly. Microbiological Ecology in Health and Disease. 2001; 13: 217-222
Bouvier M, Méance S, Bouley C, Berta JL and Grimaud JC. Effect of consumption of a milk fermented by the probiotic strain Bifidobacterium animalis DN-173 010 on colonic transit time in healthy humans Bioscience Microflora. 2001 ; 20 (2): 43-48.
Comfort digestivo
Guyonnet D, O. Chassany, P. Ducrotte, C. Picard, M. Mouret, C.H. Mercier and C. Matuchansky. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel symdrome adults in primary care. A multicentre, randomised, double-blind, controlled trial. Alimentary Pharmacology and Therapeutics. 2007; 26 (3): 475-486.
Revisiones
Picard C, Fioramonti J, Francois A, Robinson T, Neant F, Matuchansky C. Bifidobacteria as probiotic agents - physiological effects and clinical benefits. Alimentary Pharmacology and Therapeutics. 2005; 22(6): 495-512.
Otras publicaciones sobre Activia or B. animalis DN-173 010
Collado, M.C. Moreno Y. Cobo J.M. Hernandez M. Microbiological evaluation and molecular characterization of bifidobacteria strains in commercial fermented milks. European Food Research and Technology. 2006; 222 (12): 112-117
Moreno Y, Collado M.C, Ferrus M.A, Cobo J.M, Hernandez E, Hernandez M. Viability assessment of lactic acid bacteria in commercial dairy products stored at 4 C using LIVE/DEAD BacLightTM staining and conventional plate counts. International Journal of Food Science & Technology. 2006. 41(3): 275-280
Collado M.C., Moreno Y, Hernandez E, Cobo J.M., Hernandez M. In vitro viability of Bifidobacterium strains isolated from commercial dairy products exposed to human gastrointestinal conditions. Food Science and Technology International. 2005; 11 (4): 307-314
Caglar E, Sandalli N, Twetman S, Kavaloglu S, Ergeneli S, Selvi S. Effect of yogurt with Bifidobacterium DN-173 010 on salivary mutans streptococci and lactobacilli in young adults. Acta Odontol Scand. 2005; 63(6):317-20.
Lepercq P, Hermier D, David O, Michelin R, Gibard C, Beguet F, Relano P, Cayuela C, Juste C.
Increasing ursodeoxycholic acid in the enterohepatic circulation of pigs through the administration of living bacteria. Br J Nutr. 2005; 93(4):457-69.
Lepercq P, Relano P, Cayuela C, Juste C. Bifidobacterium animalis strain DN-173 010 hydrolyses bile salts in the gastrointestinal tract of pigs. Scand J Gastroenterol. 2004; 39(12):1266-71.
Van der Meulen R, Avonts L, De Vuyst L. Short fractions of oligofructose are preferentially metabolized by Bifidobacterium animalis DN-173 010. Appl Environ Microbiol. 2004; 70(4):1923-30.
Tavan E, Cayuela C, Antoine JM, Trugnan G, Chaugier C, Cassand P. Effects of dairy products on heterocyclic aromatic amine-induced rat colon carcinogenesis. Carcinogenesis. 2002; 23(3):477-83.
Tavan E, Cayuela C, Antoine JM, Cassand P. Antimutagenic activities of various lactic acid bacteria against food mutagens: heterocyclic amines. J Dairy Res. 2002; 69(2):335-41.
Thoreux K et al.; Modulation of proliferation, second messenger levels, and morphotype expression of the rat intestinal epithelial cell line IEC-6 by fermented milk. 1996. J Dairy Sci. 79: 33-43
Baricault L, Denariaz G, Houri JJ, Bouley C, Sapin C, Trugnan G. Use of HT-29, a cultured human colon cancer cell line, to study the effect of fermented milks on colon cancer cell growth and differentiation. Carcinogenesis. 1995; 16(2):245-52.
Abdelali H, Cassand P, Soussotte V, Koch-Bocabeille B, Narbonne JF. Antimutagenicity of components of dairy products. 1995; 331(1):133-41.
Abdelali H, Cassand P, Soussotte V, Daubeze M, Bouley C, Narbonne JF. Effect of dairy products on initiation of precursor lesions of colon cancer in rats. Nutr Cancer. 1995; 24(2):121-32.
Cassand P, Abdelali H, Bouley C, Denariaz G, Narbonne JF. Inhibitory effect of dairy products on the mutagenicities of chemicals and dietary mutagens. J Dairy Res. 1994; 61(4):545-52.
Moreau MC. et al.; Immunomodulating properties of a strain of Bifidobacterium used as probiotic on the fecal and cellular intestinal IgA antirotavirus responces in mice. In "Functional Foods – The Consumer, the Products, and the Evidence. Sadler MJ & Saltmarsh M. Ed. Cambridge 1998; p47-51